Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Placebo-Controlled Study of GBT440 to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT02846324 is registered in ClinicalTrials.gov with Global Blood Therapeutics as lead sponsor.

NCT NCT02846324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02846324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Placebo-Controlled Study of GBT440 to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Lead sponsor
Global Blood Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2016
Completion date
November 30, 2017
Enrollment
39 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hypoxemia, idiopathic pulmonary fibrosis